Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
about
The Role of PARP Inhibitors in the Treatment of Gynecologic MalignanciesSafe handling of oral antineoplastic medications: focus on targeted therapeutics in the home settingPoly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancerDNA-repair pathway inhibitors for the treatment of ovarian cancerPersonalized medicine: hope or hype?Function of BRCA1 in the DNA damage response is mediated by ADP-ribosylationSynaptonemal complex protein SYCP3 impairs mitotic recombination by interfering with BRCA2Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancerConcordant and opposite roles of DNA-PK and the "facilitator of chromatin transcription" (FACT) in DNA repair, apoptosis and necrosis after cisplatinLocalization of BRCA1 protein in breast cancer tissue and cell lines with mutationsFBH1 influences DNA replication fork stability and homologous recombination through ubiquitylation of RAD51FBH1 helicase disrupts RAD51 filaments in vitro and modulates homologous recombination in mammalian cellsGenomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristicsIntratumor heterogeneity: evolution through space and time6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancersMutational processes molding the genomes of 21 breast cancersSusceptibility pathways in Fanconi's anemia and breast cancerComprehensive molecular portraits of human breast tumoursBRCAness: finding the Achilles heel in ovarian cancerA de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancerMutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerPARP1 suppresses homologous recombination events in mice in vivoCytotoxic and targeted therapy for hereditary cancersTargeting DNA Replication Stress for Cancer TherapyTrial watch - inhibiting PARP enzymes for anticancer therapyProfile of olaparib in the treatment of advanced ovarian cancerTargeted agents in epithelial ovarian cancer: review on emerging therapies and future developmentsRole of Biomarkers in the Development of PARP InhibitorsThe Landscape of Pancreatic Cancer Therapeutic Resistance MechanismsPARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future PerspectivesBiomarkers in triple negative breast cancer: A reviewThe fate of chemoresistance in triple negative breast cancer (TNBC)Cancer predisposition genes: molecular mechanisms and clinical impact on personalized cancer care: examples of Lynch and HBOC syndromesDNA Damage Signalling and Repair Inhibitors: The Long-Sought-After Achilles' Heel of CancerSuccesses and Challenges of PARP Inhibitors in Cancer TherapyEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerOvarian Cancer Molecular Stratification and Tumor Heterogeneity: A Necessity and a ChallengeDevelopment, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1
P2860
Q21129302-8A13AA97-E409-405A-B93D-AD17FD6AAED5Q23923997-78A2D08E-6BF0-4EEA-B44F-0AAF6EA76146Q24187899-9C075976-A402-49C6-A9AD-4ADC63FB8A66Q24234893-906423F5-636B-42B1-9BBB-D04638C75C82Q24289193-2A826A30-35BB-415D-8DA7-AC377195F7BFQ24293084-1EB2DCD5-7CC8-4A1A-8BB1-2D935A9AB3CFQ24298264-607EC857-9802-4608-8929-F9773D1B5FC3Q24302687-CE5A905D-BBA3-4AF9-AC37-3BC8B51BB58AQ24306623-1A608F7D-C8B9-4BF9-BAC5-CBA46A9FBA86Q24308016-B7340AE3-E19D-4DF7-B8A0-E239F0A12870Q24314570-02BA4C7D-91A9-4F0D-8ED8-C593555B268EQ24338079-2E1EBF90-E01D-4AD3-A9E0-77886DB88869Q24595882-F58CE345-3F33-4AC0-9382-049B387A98B8Q24598678-1B9A1378-4851-4AE6-BCEC-F4B260745A63Q24599364-9476931C-A785-4CE3-A23C-97A129127AECQ24600350-BCCC7286-B0EA-4B76-B27A-2669B320B042Q24620915-5CD55326-9BB2-4DEE-9393-6F83C7138D3CQ24628760-D3C649D9-AF97-4C87-ADD8-F35D7DEDA959Q24630844-D1A6581A-0DAC-4716-9907-59D2B1009C8CQ24630872-4DED749E-C600-4F8E-A534-816F20D41B22Q24632225-4B63D61A-187B-40FE-9057-7099049EB560Q24632270-08D6AE7F-D836-4551-B26B-B563A6FEBA27Q24632628-00701673-0C57-484B-BEE9-87BFF022A3B2Q24632854-49A9DF3B-F513-4338-9851-C41A3642020DQ26739366-DFF2AA94-E7C9-4615-B724-1FB39AA154D6Q26739923-1300FAE5-3235-45F3-8A9B-09A1FB5E2F3EQ26745673-AFCE9207-AB6A-453B-B3D3-68684FE05069Q26749284-49082539-0CC2-4B27-9BFF-692B3F9B89BFQ26750649-EEFF5339-4522-42C7-9B71-97A00EDEBDB4Q26753159-B626A299-64C0-490F-9181-A394645AF7A5Q26765247-89DB7390-B6B3-42D5-918F-8B7530781C29Q26768661-3FB16E20-6FC6-485B-B785-4FE974B5C620Q26775094-9B27B46A-14A2-494C-A980-0BD373DD2944Q26775232-4E292E17-D1F2-45A7-B4A9-C902971E0E86Q26776258-074EC637-FFAC-424A-81AF-4533189AE9B8Q26776513-CE5F341A-2DA6-4901-97EE-98AADAE62C69Q26777131-9331E703-F186-43C0-A444-0E08CF0E4FF0Q26777310-CAEE15A6-A2AF-4F09-8669-74CD51CD2355Q26777846-7C460283-1320-46C6-9C93-FF349C0F3D72Q26778957-FF6D6AE6-262F-4547-B839-E68BE5B2BDD3
P2860
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@ast
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@en
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@nl
type
label
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@ast
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@en
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@nl
prefLabel
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@ast
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@en
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@nl
P2093
P3181
P356
P1476
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
@en
P2093
David S Boss
Helen Swaisland
James Carmichael
Jan H M Schellens
Johann S de Bono
Marja Mergui-Roelvink
Mark J O'Connor
Peter C Fong
P304
P3181
P356
10.1056/NEJMOA0900212
P407
P577
2009-07-09T00:00:00Z